Skip to main content

Actors and Networks database

The evolving field of gene and cell therapy is supported by a large community of academic, clinical, translational, regulatory and patient organisations. The Actors and Networks database maps these stakeholders in Europe and beyond, their activities, and resources they have produced. 

EuroGCT has developed and compiled this database for those interested in identifying the actors involved at each stage of the pathways bringing gene and cell therapies from lab to clinic. Coming from an academic perspective, our focus is to map information that has not been mapped elsewhere. This includes documenting the various types of interconnected regulators, patient groups actively involved along the pathways, and non-profit organisations devoted to therapy development. In its first iteration, this database does not yet include commercial partners and service providers.

Additional complementary work by other organisations on GCT stakeholders mapping can be found here.

Showing 10 of 74

Paul-Ehrlich-Institut (PEI)

Region/Country:  
  • Countries in the EU/EEA
  • Germany

Type of Actor:

  • Regulators
  • Medicines Agencies
  • National Medicines Agencies

Development Stage:

  • Fundamental Research
  • Clinical Research
  • Translational Research
  • Manufacturing
  • Commercialisation

Additional information

PEI is an Agency of the German Federal Ministry of Health. Its research and control activities promote the quality, efficacy and safety of biological medicinal products.

Resources

PEI's databases containing information about authorised medicinal products: https://www.pei.de/EN/medicinal-products/medicinal-products-node.html

QMD Services GmbH

Region/Country:  
  • Countries in the EU/EEA
  • Austria

Type of Actor:

  • Regulators
  • Medical Devices Entities
  • Notified Bodies

Development Stage:

  • Clinical Research
  • Manufacturing
  • Commercialisation

Rare Diseases Europe (EURORDIS)

Region/Country:  
  • EU/EEA

Type of Actor:

  • Patient Organisations
  • European Patient Organisations
  • Training Providers
  • Patient Involvement

Development Stage:

  • Patient and Public Involvement

Additional information

EURORDIS – Rare Diseases Europe is a unique, non-profit alliance of over 1000 rare disease patient organisations from 74 countries that work together to improve the lives of over 30 million people living with a rare disease in Europe.

Resources

SGS Belgium NV

Region/Country:  
  • Countries in the EU/EEA
  • Croatia

Type of Actor:

  • Regulators
  • Medical Devices Entities
  • Notified Bodies

Development Stage:

  • Clinical Research
  • Manufacturing
  • Commercialisation

T2Evolve (T2Evolve)

Region/Country:  
  • EU/EEA

Type of Actor:

  • Networks
  • EU Research Projects

Development Stage:

  • Clinical Research
  • Translational Research
  • Commercialisation
  • Patient and Public Involvement

Conditions and Diseases:

  • Cancer
  • Blood disorders

Additional information

T2Evolve is a consortium working to accelerate the process of developing CAR T-cell therapy in the EU.

Thalassaemia International Federation (TIF)

Region/Country:  
  • Global

Type of Actor:

  • Patient Organisations
  • International Patient Organisations

Development Stage:

  • Patient and Public Involvement

Conditions and Diseases:

  • Blood disorders

Additional information

The Thalassaemia International Federation is a non-profit, non-governmental umbrella organisation that brings together national thalassaemia and other disease-specific patient associations, health-related organisations and institutions, pharmaceutical companies, health professionals and individuals from across the world.

The Cell and Gene Therapy Catapult (CGT Catapult)

Region/Country:  
  • UK

Type of Actor:

  • Non-profit Research Organisations
  • Translational Centres

Development Stage:

  • Translational Research
  • Manufacturing
  • Commercialisation

Additional information

The CGT Catapult is an independent not-for-profit innovation and technology organisation committed to the advancement of cell and gene therapies.

The Centre for Cardiovascular Science, The University of Edinburgh (CVS)

Region/Country:  
  • UK

Type of Actor:

  • Non-profit Research Organisations
  • Academic Bodies

Development Stage:

  • Fundamental Research
  • Clinical Research
  • Patient and Public Involvement

Conditions and Diseases:

  • Heart disease

Additional information

CVS is a world-leading centre of excellence that integrates discovery, translational and clinical cardiovascular research to transform the diagnosis, treatment and management of people with heart and circulatory diseases.

Resources

The European Association Medical devices of Notified Bodies (Team-NB)

Region/Country:  
  • EU/EEA

Type of Actor:

  • Regulators
  • Medical Devices Entities
  • Medical Device Authorities
  • Supranational Medical Device Authorities

Development Stage:

  • Clinical Research
  • Manufacturing
  • Commercialisation

The European Consortium for Communicating Gene and Cell Therapy Information (EuroGCT)

Region/Country:  
  • EU/EEA
  • UK

Type of Actor:

  • Networks
  • European and Regional Networks

Development Stage:

  • Fundamental Research
  • Clinical Research
  • Manufacturing
  • Commercialisation
  • Patient and Public Involvement
  • Health Data

Additional information

EuroGCT brings together 47 partner organisations and institutions across Europe with a goal of providing reliable and accessible information about the use of cells and genetic material to treat disease.

Resources

Resources on gene and cell therapy development: https://www.eurogct.org/research-pathways; Educational resources: https://www.eurogct.org/discover-gene-and-cell-therapy/educational-resources-directory; Patient and Public Involvement resources: https://www.eurogct.org/atmp-engage; accessible information about the science behind gene and cell therapies: https://www.eurogct.org/discover-gene-and-cell-therapy
Le contenu de cette page vous a-t-il été utile ? Envoyez-nous vos commentaires